Alnylam Pharmaceuticals (NASDAQ:ALNY) Given Neutral Rating at Cantor Fitzgerald

Cantor Fitzgerald restated their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report sent to investors on Monday, Benzinga reports. The firm currently has a $220.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on ALNY. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a neutral rating to a buy rating and boosted their price target for the company from $198.00 to $370.00 in a research report on Friday, August 16th. Canaccord Genuity Group upped their target price on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a buy rating in a report on Friday, August 2nd. Stifel Nicolaus raised their target price on Alnylam Pharmaceuticals from $215.00 to $295.00 and gave the company a buy rating in a research note on Thursday, June 27th. Needham & Company LLC upped their price target on Alnylam Pharmaceuticals from $275.00 to $320.00 and gave the stock a buy rating in a research note on Friday, August 2nd. Finally, JPMorgan Chase & Co. raised their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the company a neutral rating in a research report on Monday, August 26th. Seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $279.14.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $261.73 on Monday. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $287.55. The business has a 50 day simple moving average of $258.25 and a two-hundred day simple moving average of $193.82. The firm has a market capitalization of $33.11 billion, a price-to-earnings ratio of -97.66 and a beta of 0.38.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.61. The business had revenue of $659.83 million for the quarter, compared to the consensus estimate of $447.22 million. Alnylam Pharmaceuticals’s revenue was up 107.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($2.21) EPS. As a group, sell-side analysts expect that Alnylam Pharmaceuticals will post -2.78 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $220.69, for a total transaction of $7,161,390.50. Following the sale, the director now owns 136 shares of the company’s stock, valued at approximately $30,013.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the transaction, the chief executive officer now owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director David E. I. Pyott sold 32,450 shares of the firm’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $220.69, for a total value of $7,161,390.50. Following the completion of the transaction, the director now directly owns 136 shares in the company, valued at $30,013.84. The disclosure for this sale can be found here. In the last ninety days, insiders sold 103,148 shares of company stock worth $25,658,824. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 11,943,895 shares of the biopharmaceutical company’s stock valued at $2,286,181,000 after buying an additional 287,064 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Alnylam Pharmaceuticals by 155.7% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 20,549 shares of the biopharmaceutical company’s stock worth $39,000 after purchasing an additional 12,513 shares during the period. Quattro Financial Advisors LLC lifted its position in Alnylam Pharmaceuticals by 2,517.8% during the first quarter. Quattro Financial Advisors LLC now owns 5,000 shares of the biopharmaceutical company’s stock valued at $747,000 after purchasing an additional 4,809 shares in the last quarter. Westpac Banking Corp grew its holdings in Alnylam Pharmaceuticals by 59.8% during the fourth quarter. Westpac Banking Corp now owns 1,512 shares of the biopharmaceutical company’s stock valued at $289,000 after purchasing an additional 566 shares during the period. Finally, Plato Investment Management Ltd increased its position in Alnylam Pharmaceuticals by 2,666.3% in the first quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after buying an additional 4,346 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.